Omada HealthOMDA
Recorded

Omada Health 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration46 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, and thank you for standing by. Welcome to Omada Health's third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone, and then you will hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Craig Gracey, Chief Accounting Officer and Investor Relations. Please go ahead. Thank you.

Craig GraceyChief Accounting Officer and VP of Investor Relations

Good afternoon. Welcome to Omada Health's third quarter 2026 earnings conference call. Joining me today are Sean Duffy, our co-founder and CEO, Wei-Li, our President, and Steve Cook, our CFO. Before we begin, I'd like to note that we will be discussing non-GAAP financial measures that we consider helpful in evaluating Omada's performance. You can find details on how these relate to our GAAP measures, along with the reconciliations in the press release that is available on our website. We will also make forward-looking statements based on our current expectations and assumptions, which are subject to risk and uncertainties, including factors listed in our press release and in the risk factors found in our filings with the SEC. Actual results could differ materially, and we assume no obligation to update these forward-looking statements. With that, I'll turn the call over to Sean.

Sean DuffyCo-founder and CEO

Thank you, Craig. Good afternoon, everyone, and thank you for joining us. We just reported our strongest quarter ever, and we are raising our full year 2026 financial outlook. Q3 was another solid quarter of execution. We delivered our highest quarterly revenue, gross margin progression, and our most profitable quarter to date. Revenue grew 34% year-over-year to $91 million, and gross margin was 76% on a GAAP basis and 78% on a non-GAAP basis, up from 66% and 68% a year ago. We also delivered quarterly record net income of nearly $7 million and adjusted EBITDA of $12 million. Our diabetes and hypertension programs had another productive quarter, leading all programs in year-over-year growth. Strong enrollments early in the quarter and a mix shift toward our higher valued programs helped revenue exceed our expectations.

Sean DuffyCo-founder and CEO

The cardiometabolic platform we have built continues to deliver for our members and for our customers. I also want to spend a moment to share a member quote that highlights what matters most to us here at Omada, and that's the people we serve. "I'm so excited. I have changed what I am eating and the way I'm exercising differently. My new labs today are improved, and my A1C is 6.6%, down from 7.3% three months ago. My cholesterol also improved. I have more information about diabetes and how to monitor and manage it. I'm confident using the tools, including taking my blood glucose, and I have really benefited emotionally from being able to ask questions of my health coach and the diabetes coach." Stories like that are why we exist.

Sean DuffyCo-founder and CEO

As we talk about our strong financial performance, I want to remind everybody that behind those numbers is someone working to live healthier, avoid disease progression, and get the support they need between visits with their physician. That's the mission that continues to drive us. Lastly, as we announced last quarter, on January 1, 2027, Wei-Li will become Omada's Chief Executive Officer, and I will become Executive Chair. I look forward to remaining closely involved, focused on our long-term mission, key partnerships, and strategic initiatives. 15 years ago, I started Omada with a simple belief that the space between doctor's visits, where health is won or lost, deserved real care. When I look at what this team has built, I am humbled. My commitment to this mission remains the same, even with my evolving position in this company. I have extraordinary confidence in Wei-Li and this team.

Sean DuffyCo-founder and CEO

The foundation is strong, and I'm excited to keep building on it together. With that, I'll hand things over to Wei-Li.

Wei-Li ShaoPresident

Thanks, Sean, and hello, everyone. Sean, thank you for seven years of partnership, for the foundation you built, and for continuing to lead Omada alongside me as Executive Chair. I am proud of what we've accomplished this quarter. We ended Q3 with over 1.1 million total members, up 36% year-over-year, reflecting continued demand for our cardiometabolic platform. Our diabetes and hypertension programs continue to lead our growth. Members stayed with us longer, and our ability to provide personalized care at scale reached a new level of efficiency. As we shared last quarter, we deepened our work with Health Care Service Corporation, or HCSC, one of the largest Blues plans in the country, through an agreement to extend our Prevention & Weight Health and hypertension programs into its fully insured book in three additional states, which is expected to potentially reach an additional estimated 1.5 million covered lives at launch in 2027.

Wei-Li ShaoPresident

In the fully insured business, the program is embedded at the benefit level, so clinically eligible members can enroll directly once it launches without a downstream employer sales cycle. On the PBM side, we have commercial relationships with the three largest PBMs in the country, which together processed an estimated 80% of prescription claims in 2025. Our prescribing program is in the market now with Optum. These relationships give us the broadest distribution in Omada's history for our programs. Our work across a diverse set of partners and channels also gives us insight into a range of employer needs and priorities. I want to share what we are seeing in the marketplace and how it is shaping our outlook. The GLP-1 market remains dynamic.

Wei-Li ShaoPresident

A number of employers have been spending more time making GLP-1 coverage and obesity care decisions, given the size of the commitment, the range of solutions, and the importance of getting these decisions right. Healthcare costs are also rising, creating pressure across health plans, PBMs, and employers. The importance of outcomes in ROI is top of mind for buyers, even more so than before. Omada has a history and reputation of publishing peer-reviewed research on both our outcomes and ROI. This kind of evidence has always been central to Omada's approach, and we believe it has been important in this year's selling cycle. We observed both of these factors extending the selling season deeper into Q4. Covered lives are the foundation, and enrollment is how they become members. Two things shaped enrollment and growth this quarter. The first and most important is the strength of our cardiometabolic core.

Wei-Li ShaoPresident

Our diabetes and hypertension programs, along with the broader suite around them, delivered strong results again in Q3. The mix shift toward these programs contributed to our revenue growth. These are programs where members have tended to stay engaged with us longer because of the chronic nature of the disease, which supports higher lifetime value for Omada. The second is the pace of enrollment. Strong enrollments in July and August contributed to our record Q3 revenue. As we have discussed, new enrollments have typically been strongest in the first quarter when employers launch new benefits and moderated as the year progresses. We expect new enrollments to decline sequentially in Q4, consistent with that pattern. The comparison with last year is different.

Wei-Li ShaoPresident

In H2 2025, we added a significant number of new customers and members as part of a new GLP-1 offering from an existing channel partner that included our Prevention & Weight Health program, which supported unusually strong enrollments during a period of time that does not reflect our typical seasonal pattern. Member engagement is where the durability of our model shows up. As we shared at Investor Day in September, member retention has improved to 58%, up from 43% in Q4 of 2024. That improvement is largely driven by our mix toward diabetes and hypertension, where members have tended to stay with us longer, as well as continued enhancements to our member experience and app. At the end of Q3, average tenure in our program reached a record of roughly two years and four months, up 10% year over year, and over 30% compared with three years ago.

Wei-Li ShaoPresident

That represents an increase of roughly two and a half months compared with a year ago. Longer engagement gives members time to turn early progress into lasting improvements in their health. We provide more intensive clinical care early on to help members establish strong habits and continue to adapt their care as their habits take hold. When members can sustain their progress with less frequent and less intensive support, our cost to serve declines and margins improve, while billing remains tied to the care we continue to provide. We also have new evidence of the clinical value of our care.

Wei-Li ShaoPresident

Recently published peer-reviewed research found that members in our GLP-1 Care Track lost nearly twice as much weight as GLP-1 users in non-Omada care at 12 weeks, a 6% average weight loss compared with 3.3%, with about twice the reduction in body fat and greater preservation of muscle mass on average. These results speak to the value of pairing medication with the type of care our GLP-1 Care Track provides. Delivering these outcomes consistently requires continued development of our care model and the technology that supports it. We previously said that 2026 was shaping up to be what we feel is our most innovative year. Many of this year's enhancements launched in Q3. We improved onboarding to help members start care sooner with goals tailored to their circumstances. As care continues, personalized reminders and recommendations help them get timely guidance and stay on track.

Wei-Li ShaoPresident

We also strengthened nutrition support and meal reviews that combine human and AI feedback, helping members build healthier eating habits that can support lasting improvements in their health. Our work in cholesterol management, GLP-1 prescribing, and Flex Care are aimed at further deepening engagement in 2027. Our focus is on bringing personalized care to more members as we scale. As we shared at Investor Day, automation and AI have given our care teams more capacity to apply their clinical expertise and tailor care to each member's needs. That has helped to support more members per care team while continuing to deliver even more personalized care. Our cost of care, as measured by non-GAAP cost of revenue per total member on a trailing 12-month basis, reached an all-time low of $81 in Q3, down from $85 in Q2 and $94 in Q3 2025.

Wei-Li ShaoPresident

This quarter shows what we have built at Omada. Our commercial relationships give us broad reach, and our cardiometabolic programs have driven growth. Our program mix has supported longer member tenure, and our cost to serve has decreased, all of which contributed to another solid quarter's performance. Our platform gives customers a choice of programs to meet the needs of their covered populations. Recently published research suggests that roughly 188 million insured American adults have a condition we treat, and one-third of our customers already work with us across more than one condition. This year, we added prescribing offering and cholesterol as a condition area, further broadening the options available to our customers. This quarter also strengthened our financial position. We have been profitable for two straight quarters. We have had a strong balance sheet and no debt, and that gives us real flexibility in how we deploy capital.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day